drugset / Trial / NCT06413992
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.
Timeline
- Start
- 2024-05-10
- Primary completion
- 2026-06-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 150 mg | Oral |
| Background | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |